PRNB - Principia Biopharma Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Principia Biopharma Inc.

220 East Grand Avenue
South San Francisco, CA 94080
United States
650-416-7700
http://www.principiabio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees71

Key Executives

NameTitlePayExercisedYear Born
Mr. Martin BablerPres, CEO & Director790.33kN/A1965
Ms. Stefani A. WolffChief Devel. Officer494.23kN/A1962
Dr. Dolca Thomas M.D.Chief Medical Officer366.83kN/A1971
Mr. Christopher Y. ChaiChief Financial OfficerN/AN/A1967
Dr. David M. GoldsteinChief Scientific OfficerN/AN/A1966
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.

Corporate Governance

Principia Biopharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.